FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896857324> ?p ?o ?g. }

• W2896857324 abstract "Purpose of the study. To evaluate the effectiveness and safety of the use of rebamipide as part of the triple eradication therapy (ET) scheme of Helicobacter pylori infection. Materials and methods. A prospective, randomized comparative study included 94 patients with uncomplicated H. pylori-associated stomach / duodenal ulcer. In the process of randomization, patients are divided into three groups depending on the intended therapy. The first group (n=36) received a classical triple scheme of the first-line ET (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day) for 10 days. Patients of the second group (n=33) were assigned a classical triple scheme of ET with the inclusion of rebamipide (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day, rebamipide 100 mg 3 times a day day) for 10 days. Patients of the third group (n=25) were assigned a classical triple scheme of ET with the inclusion of rebamipide (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day, rebamipide 100 mg 3 times a day) in for 10 days, with the prolongation of the administration of rebamipide for the next 20 days. The effectiveness of ET was determined by the respiratory test after 6 weeks after the end of treatment. Adverse events were recorded by patients in specially developed diaries. All patients with gastric ulcer at the 6th week underwent a histological examination of the biopsy specimens of the antrum and the body of the stomach, assessing the inflammatory activity of the process on a point system in accordance with the updated Sydney system. Results and discussion. Efficiency of H. pylori eradication in the first group was 77.7% (ITT), 82.3% (PP), in the second group - 81.8% (ITT), 84.4% (PP), and in the third group - 84% (ITT), 87.5% (PP). The use of rebamipide in the triple ET regimen was associated with an increase in H. pylori eradication efficiency, both with simultaneous use with the scheme [odds ratio (OR) 1.16; 95% confidence interval (CI) 0.32-4.24], and with subsequent prolonged admission (OR 1.5, 95% CI 0.34-6.7). A somewhat more pronounced dynamics of the epithelization of erosive and ulcerative changes in the mucous membrane of the stomach and duodenum to the 21st and 28th days in the third group of patients was noted. The incidence of adverse events between the groups was comparable: 22.2% in the first group, 24.2% in the second group and 20% in the third group. In the pathomorphological evaluation of biopsy specimens of patients with gastric ulcer at the 6th week after the treatment, significant differences were revealed between the first and third groups in terms of the inflammatory activity in the antrum stomach (2±0.63 vs. 1.4±0.52; p=0,0399). The conclusion. The inclusion of rebamipide in the classical triple scheme of H. pylori ET increases the effectiveness of treatment and does not affect the safety profile. In the post-eradication period, it is advisable to continue the use of rebamipide to potentiate the repair of the gastric mucosa and regress the inflammatory processes." @default.
• W2896857324 created "2018-10-26" @default.
• W2896857324 creator A5003898727 @default.
• W2896857324 creator A5027834011 @default.
• W2896857324 creator A5030694515 @default.
• W2896857324 creator A5048357358 @default.
• W2896857324 creator A5083143529 @default.
• W2896857324 date "2018-08-15" @default.
• W2896857324 modified "2023-10-18" @default.
• W2896857324 title "Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study" @default.
• W2896857324 cites W1579181493 @default.
• W2896857324 cites W1676834274 @default.
• W2896857324 cites W1990890990 @default.
• W2896857324 cites W1996625135 @default.
• W2896857324 cites W2034388692 @default.
• W2896857324 cites W2065005644 @default.
• W2896857324 cites W2088494763 @default.
• W2896857324 cites W2109224010 @default.
• W2896857324 cites W2140647906 @default.
• W2896857324 cites W2565770720 @default.
• W2896857324 cites W2570938003 @default.
• W2896857324 cites W2593038707 @default.
• W2896857324 cites W2609752905 @default.
• W2896857324 cites W2756368833 @default.
• W2896857324 cites W2770273169 @default.
• W2896857324 cites W4211029205 @default.
• W2896857324 doi "https://doi.org/10.26442/terarkh201890827-32" @default.
• W2896857324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30701936" @default.
• W2896857324 hasPublicationYear "2018" @default.
• W2896857324 type Work @default.
• W2896857324 sameAs 2896857324 @default.
• W2896857324 citedByCount "15" @default.
• W2896857324 countsByYear W28968573242019 @default.
• W2896857324 countsByYear W28968573242020 @default.
• W2896857324 countsByYear W28968573242022 @default.
• W2896857324 crossrefType "journal-article" @default.
• W2896857324 hasAuthorship W2896857324A5003898727 @default.
• W2896857324 hasAuthorship W2896857324A5027834011 @default.
• W2896857324 hasAuthorship W2896857324A5030694515 @default.
• W2896857324 hasAuthorship W2896857324A5048357358 @default.
• W2896857324 hasAuthorship W2896857324A5083143529 @default.
• W2896857324 hasBestOaLocation W28968573241 @default.
• W2896857324 hasConcept C126322002 @default.
• W2896857324 hasConcept C168563851 @default.
• W2896857324 hasConcept C197934379 @default.
• W2896857324 hasConcept C204243189 @default.
• W2896857324 hasConcept C2776409635 @default.
• W2896857324 hasConcept C2776962512 @default.
• W2896857324 hasConcept C2777367493 @default.
• W2896857324 hasConcept C2777498785 @default.
• W2896857324 hasConcept C2779708577 @default.
• W2896857324 hasConcept C2781025758 @default.
• W2896857324 hasConcept C501593827 @default.
• W2896857324 hasConcept C71924100 @default.
• W2896857324 hasConcept C86803240 @default.
• W2896857324 hasConcept C89423630 @default.
• W2896857324 hasConcept C90924648 @default.
• W2896857324 hasConceptScore W2896857324C126322002 @default.
• W2896857324 hasConceptScore W2896857324C168563851 @default.
• W2896857324 hasConceptScore W2896857324C197934379 @default.
• W2896857324 hasConceptScore W2896857324C204243189 @default.
• W2896857324 hasConceptScore W2896857324C2776409635 @default.
• W2896857324 hasConceptScore W2896857324C2776962512 @default.
• W2896857324 hasConceptScore W2896857324C2777367493 @default.
• W2896857324 hasConceptScore W2896857324C2777498785 @default.
• W2896857324 hasConceptScore W2896857324C2779708577 @default.
• W2896857324 hasConceptScore W2896857324C2781025758 @default.
• W2896857324 hasConceptScore W2896857324C501593827 @default.
• W2896857324 hasConceptScore W2896857324C71924100 @default.
• W2896857324 hasConceptScore W2896857324C86803240 @default.
• W2896857324 hasConceptScore W2896857324C89423630 @default.
• W2896857324 hasConceptScore W2896857324C90924648 @default.
• W2896857324 hasLocation W28968573241 @default.
• W2896857324 hasLocation W28968573242 @default.
• W2896857324 hasOpenAccess W2896857324 @default.
• W2896857324 hasPrimaryLocation W28968573241 @default.
• W2896857324 hasRelatedWork W1016986967 @default.
• W2896857324 hasRelatedWork W1887880519 @default.
• W2896857324 hasRelatedWork W1997839897 @default.
• W2896857324 hasRelatedWork W2050498853 @default.
• W2896857324 hasRelatedWork W2090913673 @default.
• W2896857324 hasRelatedWork W2114338393 @default.
• W2896857324 hasRelatedWork W2125174157 @default.
• W2896857324 hasRelatedWork W2162337554 @default.
• W2896857324 hasRelatedWork W2378113641 @default.
• W2896857324 hasRelatedWork W248670409 @default.
• W2896857324 isParatext "false" @default.
• W2896857324 isRetracted "false" @default.
• W2896857324 magId "2896857324" @default.
• W2896857324 workType "article" @default.